Loading…
Electra Therapeutics, Inc.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ETRA.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DNAGinkgo Bioworks Holdings, Inc. | $10.46 | — | 1.6x | — | -59.94% | $704.38M |
| VSTMVerastem, Inc. | $7.77 | — | 8.3x | — | -471.16% | $703.68M |
| FTHFaeth Therapeutics, Inc. | $27.77 | — | 4.1x | — | -195.26% | $717.59M |
| IMMPIMMUTEP Ltd | $4.88 |
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.
Company description provided by Yahoo Finance.
| — |
| 16.4x |
| — |
| -77.31% |
| $719.18M |
| COLLCollegium Pharmaceutical Inc | $22.63 | 17.8x | 2.4x | — | 17.61% | $701.51M |
| SOPHSOPHiA GENETICS SA | $8.49 | — | 8.7x | — | -101.22% | $722.74M |